JB Chemicals & Pharmaceuticals Limited has informed the Exchange about Investor Presentation
JBCHEPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JB Chemicals & Pharmaceuticals submitted its Q1 FY26 investor presentation along with financial results. Revenue grew 9% YoY to INR 1,094 crores, driven by a strong 14% growth in domestic formulations (INR 678 crores) and 8% growth in CDMO business (INR 115 crores). International formulations dipped 2% to INR 283 crores. Operating EBITDA rose 13% to INR 330 crores, with margins crossing 30% for the first time at 30.2% (vs 29.0% in Q1 FY25), supported by higher gross margins of 68.3%. Net profit grew 14% to INR 202 crores. The company highlighted that it is the fastest-growing among the top 25 pharma firms in India, now ranked #22 in the IPM with 6 brands in the Top 300.
Positive for shareholders — strong domestic growth, margin expansion above 30% for the first time, and healthy 14% profit growth signal robust operational performance. The management's focus on profitable growth and cost optimization could continue to support earnings momentum.